Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment

[1]  R. Mcquade,et al.  Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors. , 2011, European journal of pharmacology.

[2]  L. Ferini-Strambi,et al.  Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome , 2011, Neurology.

[3]  O. Rascol,et al.  Pramipexole for the treatment of early Parkinson’s disease , 2011, Expert review of neurotherapeutics.

[4]  Fuquan Zhang,et al.  Converging evidence implicates the dopamine D3 receptor gene in vulnerability to schizophrenia , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[5]  T. Murata,et al.  Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia. , 2011, Journal of clinical psychopharmacology.

[6]  C. Reynolds.  Physician's Desk Reference , 2008 .

[7]  C. Aiken.  Pramipexole in psychiatry: a systematic review of the literature. , 2007, The Journal of clinical psychiatry.

[8]  H. Koh,et al.  KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia , 2005, Pharmacology Biochemistry and Behavior.

[9]  R. Baldessarini,et al.  Inpatient antipsychotic drug use in 1998, 1993, and 1989. , 2002, The American journal of psychiatry.

[10]  A. Stoll,et al.  Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. , 2000, The American journal of psychiatry.

[11]  S. Wolfarth,et al.  Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. , 1999, European journal of pharmacology.

[12]  S. Pallanti,et al.  Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. , 1999, The American journal of psychiatry.

[13]  H. Wikström,et al.  Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907. , 1998, European journal of pharmacology.

[14]  J. Sawynok.  Adenosine receptor activation and nociception. , 1998, European journal of pharmacology.

[15]  H. Volz,et al.  Pramipexole as adjunct to haloperidol in schizophrenia Safety and efficacy , 1996, European Neuropsychopharmacology.

[16]  C. Gerfen,et al.  A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Wetzel,et al.  Dopamine agonists in schizophrenia: a review , 1995, European Neuropsychopharmacology.

[18]  M. Martres,et al.  Opposing Roles for Dopamine D2 and D3 Receptors on Neurotensin mRNA Expression in Nucleus Accumbens , 1994, The European journal of neuroscience.

[19]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[20]  S. Kapur,et al.  Elevation of prolactin levels by atypical antipsychotics. , 2002, The American journal of psychiatry.

[21]  C. Tamminga,et al.  Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia , 1998, Journal of Neural Transmission.

[22]  M. Johns.  Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. , 1993, Chest.

[23]  W. Kissling,et al.  Erste klinische Erfahrungen mit dem neuen Dopamin-Autorezeptoragonisten SND 919 , 1992 .